MMP9 and Miyoshi myopathy: Finally, we identified a subset of EMT markers regulated by PRMT5 in MM, including E‐cadherin, N‐cadherin, α‐smooth muscle actin and MMP9, indicating that targeting PRMT5 could hamper this crucial process for cancer progression.